This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Updated from 2:19 p.m. EDT

Gains from intercompany deals balanced out losses brought about by analyst predictions, and health stocks set off on a slightly good note Wednesday.

First, for those who browsed Yahoo! Finance this morning: No, Teva Pharmaceutical (TEVA) didn't burst 80% and Neurochem (NRMX) wasn't really trading at minus-$12. Although such action would've resulted in a much more dramatic Winners & Losers column, the glitch appears to be fixed now.

Oculus Innovative Sciences (OCLS) did trade actively after the medical-instruments company announced a 10-year licensing agreement with the Drug Enhancement Company of America for the rights to Oculus' first-response pen-like applicator for cuts, minor burns and skin irritations, Microcyn Technology. The agreement, which gives DECA an exclusive worldwide license on the technology, may also provide Oculus payments of up to $47.5 million, according to the company. After rising more than 9% earlier in the day, Oculus closed down 1.1%, or 8 cents, to $7.16.

American Oriental Bioengineering (AOB) signed a letter of intent to acquire Changchun Xinan Pharmaceutical Group, a fellow China-based company. American Oriental Bioengineering has 90 days to enter a definitive agreement and close the transaction according to the letter of intent. It anticipates an all-cash deal not exceeding $30 million. American Oriental Bioengineering's shares rose 27 cents, or 2.9%, to $9.71.

Elsewhere, LifeCell (LIFC) said Wednesday that it received 510(k), or premarket notification, clearance from the U.S. Food and Drug Administration for Strattice tissue matrix. The product is for soft tissue repair, including breast reconstruction and hernia repair. LifeCell gained $1.70, or 6% to $29.99.

LifeCell is a component of the Nasdaq Biotechnology Index, which was up 9.59, or 1.2%, to 818.48.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs